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ABSTRACT
The use of natalizumab for highly active
relapsing-remitting multiple sclerosis (MS) is inﬂuenced
by the occurrence of progressive multifocal
leukoencephalopathy (PML). Through measurement of
the anti-JCV antibody index, and in combination with
the presence or absence of other known risk factors, it
may be possible to stratify patients with MS according to
their risk of developing PML during treatment with
natalizumab and detect early suspected PML using MRI
including a diffusion-weighted imaging sequence. This
paper describes a practical consensus guideline for
treating neurologists, based on current evidence, for the
introduction into routine clinical practice of anti-JCV
antibody index testing of immunosuppressant-naïve
patients with MS, either currently being treated with, or
initiating, natalizumab, based on their anti-JCV antibody
status. Recommendations for the frequency and type of
MRI screening in patients with varying index-associated
PML risks are also discussed. This consensus paper
presents a simple and pragmatic algorithm to support
the introduction of anti-JCV antibody index testing and
MRI monitoring into standard PML safety protocols, in
order to allow some JCV positive patients who wish to
begin or continue natalizumab treatment to be managed
with a more individualised analysis of their PML risk.
INTRODUCTION
The use of natalizumab, for highly active
relapsing-remitting MS, is inﬂuenced by the occur-
rence of progressive multifocal leukoencephalopa-
thy (PML).1 The risk of developing PML requires
the patient and the treating physician to carefully
consider the beneﬁts and risks of natalizumab.
Although alternative licensed treatment options in
this clinical scenario are available such as ﬁngoli-
mod2 3 and alemtuzumab,4 5 when given the
choice some patients decide to start or remain on
natalizumab and are willing to accept a certain level
of risk of PML.
Clinical vigilance during treatment with natalizu-
mab is essential to optimise physicians’ ability to
identify PML in its early stages and to maximise
the potential for favourable outcomes (see Berger
et al6 for a discussion regarding the clinical features
of PML). Additionally, a number of studies have
reported that MRI detection of presymptomatic
PML may be associated with improved outcomes,
including potential reductions in morbidity and
mortality, although as the number of patients iden-
tiﬁed in the asymptomatic stage remains small this
needs further longitudinal conﬁrmation.7–12
The development of PML during treatment with
natalizumab is associated with the presence of
anti-JCV antibodies, treatment duration, especially
beyond 2 years, and immunosuppressant use before
receiving natalizumab.13 Determination of anti-JCV
antibody status and assessment of other risk factors
has, in recent years, enabled a clearer understand-
ing of the risk of PML occurring during therapy
with natalizumab; which helps support decision-
making regarding the risks of initiating, or continu-
ing with, treatment.14 15 Pharmacovigilance in the
UK and Ireland is well established. This paper uses
data collected from worldwide clinical trial and
postmarketing settings to support the notion that
measuring the patient’s anti-JCV antibody index, in
combination with the presence or absence of the
other known risk factors, might allow further strati-
ﬁcation of these patients according to their risk of
developing PML.16
A group of neurologists from the UK and Ireland
were convened by Biogen at an advisory board with a
view to examining the data and potential utility of
the anti-JCVantibody index to help neurologists treat
patients. Following this advisory board, the group
independently convened and took the decision to ask
Biogen to support the development of this practical
consensus guideline for neurologists. The authors did
not receive ﬁnancial reimbursement for this work.
The expert group recognised that current evidence
was often not of high level, resulting in several areas
of doubt and uncertainty. The group felt, however,
that it would be of practical value to develop
up-to-date guidelines for monitoring patients receiv-
ing natalizumab by stratifying PML risk based on
anti-JCV antibody index. No data were available at
the time of writing to support some of the guidance
and, in such cases, recommendations were based on
the clinical experience of the authors. In addition,
the authors’ deliberations identiﬁed several areas that
would beneﬁt from further research.
RISKS OF PML ASSOCIATED WITH
NATALIZUMAB TREATMENT
PML is a subacute, evolving infectious disease of
oligodendrocytes and astrocytes of the central
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nervous system (CNS).14 15 Typically, PML affects the juxtacorti-
cal and deep white matter of the frontal and parietal lobes, as
well as the cortical and deep grey matter.17 PML is an oppor-
tunistic infection that is almost exclusively associated with
immunosuppression. The condition occurs most commonly in
HIV-infected individuals; but has also been reported in those
with underlying malignancies, organ transplants, rheumatic dis-
eases, and sarcoidosis; but not untreated immune-based dis-
eases.15 More recently, PML has become associated with
biological treatments that act via immune modulation, including
natalizumab.15
It is estimated that almost 60% of the population of Europe
have been infected with JCV.18 The virus is typically benign and
resides in the gut, kidneys, bone marrow and lymphoreticular
system.15 PML is caused by a mutating, neurotropic strain of
JCV,14 but it is not entirely clear what drives this conversion
within natalizumab-treated patients with MS. Adaptive genetic
mutations allow for the development of a pathogenic JCV,14 15
which produces a lytic infection of oligodendrocytes, astrocytes
and neuronal cells. It is thought that natalizumab may then
facilitate the development of overt PML by affecting CNS
immune surveillance at numerous levels.14
The presence of anti-JCV antibodies is a well-characterised
factor for the development of PML among patients with MS
treated with natalizumab. Early reports identiﬁed a prevalence
of 100% for anti-JCV antibody-positivity among natalizumab-
treated patients with MS who later developed PML.19 20 In
postmarketing analyses, as of 3 June 2015, 138 800 patients
worldwide had received natalizumab, with overall PML inci-
dence of 3.96 per 1000 patients (Biogen MedInfo. https://
medinfo.biogen.com accessed 1 July 2015). In patients without
previous immunosuppressant use, PML incidence rose from 1/
1000 after 1–24 months natalizumab exposure, to 5 and 6/1000
after 25–48 and 49–72 months. In patients with a history of
immunosuppressant use, PML incidence was 2, 11 and 9/1000
after 1–24, 25–48 and 49–72 months, respectively.21 However,
it should be noted that the absolute number of diagnosed PML
cases globally may depend on the robustness of pharmacovigi-
lance in each country. Additionally, while JCV antibody positiv-
ity is a risk factor, PML can potentially occur in JCV-antibody
negative patients.
Of the 566 cases of PML reported to Biogen, 296
natalizumab-associated PML cases had serology samples tested
for anti-JCV antibodies at least 6 months before a diagnosis of
PML. Overall, 292 of these 296 samples (99.0%) tested positive
for anti-JCV antibodies before PML diagnosis and four (1.0%)
tested anti-JCV antibody-negative.
Of the latter four patients, two had a JCV negative status
reported 8 and 9 months before the diagnosis or PML. The
third patient had an anti-JCV antibody negative test result
5.7 months before PML diagnosis, and an anti-JCV antibody
positive test result at the time of PML diagnosis. No additional
pre-PML samples were available for testing (Biogen MedInfo
(https://medinfo.biogen.com accessed 1 July 2015). The fourth
was diagnosed with PML 2 weeks after last negative anti-JCV
antibody testing. However, the patient tested positive for anti-
bodies at diagnosis.22
Based on the available information at the time of European
Medicines Agency (EMA) guideline issue and owing to the
intrinsic variability of anti-JCV antibody status over time, the
Committee for Medicinal Products for Human Use currently
recommends six-monthly anti-JCV antibody testing to allow for
earlier identiﬁcation of patients who change their antibody
status from negative to positive.23
EPIDEMIOLOGY OF PML INFECTION DURING
NATALIZUMAB TREATMENT
The currently known risk of developing PML during treatment
with natalizumab is highest for patients with MS who have
anti-JCV antibody-positive status, have received any prior
immunosuppressant therapy of any duration at any time, and
have been treated with natalizumab for ≥25 months. The esti-
mated incidence of PML in this subgroup of patients is 11.1/
1000 (or one in 90) patients.19
Patients who possess all three of these risk factors should be
closely monitored for potential signs of PML onset during nata-
lizumab treatment and for 6 months post-treatment.13–15 This
time frame allows surveillance to capture PML cases potentially
associated immunosuppression associated with natalizumab that
persists beyond the 3-month wash out.24 25 The consensus
group agreed that MRI scanning should be performed when
patients discontinue natalizumab. The group suggested carefully
examining the last on-natalizumab scan, followed by an add-
itional ‘safety scan’ 3 months after the end of natalizumab treat-
ment. The latter could act as a new baseline scan before starting
the next treatment. Subsequent scanning should follow the clini-
cian’s practice or local practice for the new agent.
JCV positivity
Epidemiological analyses have uniformly shown that the preva-
lence of anti-JCV antibody-positivity is signiﬁcantly associated
with increasing MS patient age, male gender, and country of
residence.18 26–28 In the JCV Epidemiology in MS ( JEMS) trial
—which included more than 7700 patients with MS from
across 10 different countries—the prevalence of anti-JCV posi-
tivity across Europe ranged from 48.8% in the UK and 51.0%
in Ireland, to 69.5% in Portugal.18 Cross-sectional data showing
the relationship between rising anti-JCV antibody index and
duration of natalizumab therapy shows no association.29
However, one of the co-authors of this consensus statement
recently reported an increasing anti-JCV index over time in a
UK cohort of natalizumab treated patients. This observation was
greater than expected due to age alone and merits further evalu-
ation in other populations.30 Vennegoor et al reported 4 of 193
patients treated with natalizumab who developed PML. All four
patients with PML showed consistently high serum anti-JCV
antibodies before the PML diagnosis. But, in contrast to some
other studies,27 the anti-JCV antibody indices did not increase,
possibly because of a ceiling in the assay.31
The risk of developing PML during natalizumab treatment is
signiﬁcantly lower among anti-JCV antibody-negative patients
with MS compared with those who are seropositive. In
STRATIFY-2, the estimated PML incidence was 0.09/1000 (or 1
in 11 111) patients among individuals who were anti-JCV
antibody-negative when starting treatment, but who subse-
quently seroconverted prior to PML diagnosis.29 The presence
of anti-JCV antibodies has been estimated to increase the risk of
developing PML by more than 40-times, with an incidence of
3.9/1000 (or 1 in 263) patients (p<0.001) among those treated
for at least 1 month with natalizumab.19
Duration of treatment with natalizumab
Elevated PML risk during natalizumab therapy is also associated
with an increasing duration of natalizumab treatment. In
JCV-positive patients, the greatest increase in PML risk appear
after 24 months of natalizumab therapy: the risk of PML is 0.6/
1000 (or 1 in 1667) patients from 1 to 24 months of natalizu-
mab exposure and 5.2/1000 (or 1 in 192) patients from month
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25 to 48 in immunosuppressant-naïve patients.16 Data beyond
4 years of therapy are limited in this cohort, although the risk
of PML has been estimated to be 5.4/1000 (or 1 in 185) after
49–72 months of natalizumab exposure.16 A recent analysis
reported that the risk of PML was 1.37 and 10.12/1000
anti-JCV antibody positive patients after 49–72 months of nata-
lizumab exposure for patients with indices of ≤1.5 and >1.5,
respectively, although relatively few patients received treatment
for more than 49 months.32
Previous use of immunosuppressive therapies
Prior immunosuppressant therapies that were most commonly
given to 68 patients who developed natalizumab-related PML
included (some patients received more than one agent): mitox-
antrone (38/68 (55.9%) conﬁrmed PML cases), cyclophospha-
mide (14/68 (20.6%) conﬁrmed PML cases), azathioprine (11/
68 (16.2%) conﬁrmed PML cases), methotrexate (9/68 (13.2%)
conﬁrmed PML cases), mycophenolate mofetil (6/68 (8.8%)
conﬁrmed PML cases), and other immunosuppressants (8/68
(11.8%) conﬁrmed PML cases).19 More data are required
regarding the mode of action of emerging disease-modifying
therapies before their association with PML can be fully deter-
mined. However, the risk of PML has been reported to be 0.31/
1000 (or 1 in 3226) patients for immunosuppressant-naïve
versus 0.88/1000 (or 1 in 1136) patients with prior immuno-
suppressant therapy.19
DIAGNOSIS OF PML IN ASYMPTOMATIC STAGES MAY
IMPROVE OUTCOMES
The overall rate of survival among all patients diagnosed with
natalizumab-associated PML is around 70–80%.15 33–35 Despite
such observations, patients who survive PML often have serious
morbidity, associated with substantial and permanent disabil-
ity.33 34 In this regard, it has been reported that PML may be
detected in the presymptomatic phase using routine surveillance
MRI, and that early detection and treatment of suspected PML
could lead to improved outcomes.7–11 35 36
An analysis of postmarketing surveillance data collected on
336 patients who developed natalizumab-associated PML
reported that 76% survived during a mean follow-up from PML
diagnosis of 16.1 months. The mean time from diagnosis to
death was 4.7 months for non-survivors. Younger age at diagno-
sis, less functional disability before PML diagnosis, lower JC
viral load (based on in situ hybridisation for JCV DNA) at diag-
nosis, and more localised brain involvement based on MRI at
diagnosis seemed to predict improved survival. Patients rapidly
stabilised following the initial phase of natalizumab-associated
PML, and EDSS showed a high correlation with Karnofsky
Performance Scale scores.35
Data suggest that patients who are asymptomatic at the time
of diagnosis of PML, compared with those who are symptom-
atic, may have less functional disability and improved survival at
12 months. Mean Expanded Disability Status Scale (EDSS)
scores were 4.1—that is, on average, fully independently ambu-
lant—among patients asymptomatic at diagnosis and 5.4—not
able to walk 200 m without aid or rest—in those who were
symptomatic (p=0.038). Overall survival was 96.7% for asymp-
tomatic and 75.4% for symptomatic patients, respectively,
through a mean follow-up of 13.4 and 11.2 months.12
Early PML diagnosis is also critical in limiting the degree of
permanent brain damage before immune reconstitution can be
achieved.33 This further reinforces the need to put in place strat-
egies to enable the earliest possible identiﬁcation of potential
cases of PML during treatment with natalizumab, alongside
maintained clinical vigilance. However, the current data includes
small numbers of patients and further data are needed to
conﬁrm the impact of early identiﬁcation on clinical outcomes.
The anti-JCV antibody index and PML risk stratiﬁcation
The anti-JCV antibody index is a function of a patient’s
anti-JCV antibody level. The presence or absence of anti-JCV
antibodies in serum is qualitatively assessed using an ELISA
method via the STRATIFY JCV DxSelect assay (Focus
Diagnostics, Cypress, California, USA).37 The anti-JCV antibody
index value is the optical density of an anti-JCV antibody-
positive serum sample, normalised to an assay calibrator.16 This
enables the speciﬁc anti-JCV antibody level to be quantiﬁed for
individual patients.26–28 38 Laboratories in the UK and Ireland
do not automatically report the anti-JCV antibody index, so the
test must be requested by the ordering clinician.38 However,
index data are available to clinicians across Europe via Unilabs.
The utility of the anti-JCV antibody index in deﬁning PML
risk among anti-JCV antibody-positive patients with MS has
been investigated in a longitudinal study. The study included
data from 2522 non-PML and 71 patients with PML included
in natalizumab clinical studies—including AFFIRM,
STRATIFY-1, and STRATIFY-2—and from postmarketing
sources.16 Data from 51 patients with PML in this study indi-
cates that the anti-JCV antibody index value was signiﬁcantly
higher in patients who developed PML at least 6 months prior
to diagnosis, compared with non-PML patients (P<0.0001).
This pattern was not seen in those who had previously used
immunosuppressants (for the purposes of clarity, glatiramer
acetate and β interferon are not classiﬁed as immunosuppres-
sants). The anti-JCV antibody index value appears to predict the
risk of subsequently developing PML during treatment with
natalizumab, with high sensitivity but low speciﬁcity because
many patients not developing PML also have high anti-JCV anti-
body levels (eg, 57.1% of non-PML patients have an index
>1.5).16
Based on their anti-JCV antibody index and duration of nata-
lizumab treatment, anti-JCV antibody-positive,
immunosuppressant-naïve patients with MS may be stratiﬁed
into one of two practical risk management groups: those with
an index value ≤1.5 and those with an index >1.5 (see online
supplementary data, table S1A). Patients with an anti-JCV anti-
body index ≤1.5 have a lower PML risk compared with the
total population of anti-JCV antibody-positive patients. All those
with an index value of ≤1.5 carry a 0.17/1000 (or 1 in 5882) or
lower PML risk in months 1–24 of natalizumab therapy. In
months 25–48 of therapy, an index value of ≤0.9 carries a risk
of 0.51/1000 (or one in 1961), rising to a risk of 1.13/1000 (or
1 in 885) if index values increase to 1.5. During months 49–72,
an index value of ≤0.9 carries a risk of 0.58/1000 (or 1 in
1724), rising to 1.37/1000 (or 1 in 730) if index values increase
to 1.5.32
The PML risk among patients with an anti-JCV antibody
index >1.5 is also low during months 1–24 of natalizumab
therapy—with an estimated risk of 1.17/1000—but increases
markedly to 8.83/1000 (or 1 in 113) in months 25–48 and rises
to a level of 10.12/1000 (or 1 in 99) from months 49–72.32
While index values and their relation to risk of PML exist on
a spectrum and are not absolute, the consensus group concluded
that the ≤1.5 and >1.5 index values provide a reasonable
numerical cut-off for implementation of a practical protocol,
based on the large increase in risk based on an index value of
greater than 1.5 beyond 2 years of treatment. Based on critical
assessment of the limited data available, combined with the
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opinion and experience of the author group, it is suggested that
patients with an anti-JCV antibody index >1.5 are considered
to require high-frequency MRI monitoring to mitigate their risk
of developing PML during natalizumab therapy, and those with
an anti-JCV antibody index ≤1.5 are considered to require
moderate-frequency MRI monitoring, as outlined in the algo-
rithm for MRI-based PML safety monitoring described in the
following section (ﬁgure 1). When compared with the risk cal-
culation without index (as shown in see online supplementary
data, table S1B), application of anti-JCV antibody index data in
the stratiﬁcation of PML risk seems to improve the accuracy
with which overall risk can be estimated. This protocol allows
more patients who are anti-JCV antibody-positive to continue
on natalizumab, albeit incurring a high-frequency MRI monitor-
ing scheme in the 57.1% of anti-JCV antibody positive patients
who have >1.5 index and a moderate-frequency MRI monitor-
ing scheme in the remaining 42.9% of patients with ≤1.5
index.16
Longitudinal data suggest that anti-JCV antibody index values
may ﬂuctuate over time,16 although an upper-limit to the assay
may limit the ability to track changes at high indices.31 Over a
period of 18 months, 87% of patients who tested anti-JCV
antibody-negative at baseline remained negative during subse-
quent testing and 97% of patients who tested anti-JCV
antibody-negative at baseline remained below an anti-JCV anti-
body index threshold of 1.5 (at 18 months). The remainder of
patients (3%) seroconverted to an index of >1.5 during
18 months of follow-up.16
Among patients who were anti-JCV antibody-positive, 84%
who had an index >1.5 maintained this level for at least
6 months prior to a diagnosis of PML and during subsequent
tests. Longitudinal data were relatively similar for index thresh-
olds of 0.9, 1.2 and 1.5.16 Thus, the consensus panel concluded
that while there is no evidence that a rising level indicates an
increased risk of PML, there are some data to support the prac-
tical protocol cut-off of 1.5. Serial measurement of JCV status
and index in JCV-positive patients also seems sensible based on
these observations.
By providing an additional level of sensitivity compared with
previous estimates of PML risk, these data appear to be
extremely useful in guiding treatment decisions in
immunosuppressant-naïve patients with MS. As such, it is
strongly recommended that serial anti-JCV antibody index
testing is incorporated into standard safety monitoring protocols
for patients with MS considering or undergoing treatment with
natalizumab.
CONSENSUS GUIDELINE PROPOSAL
Recommended guidelines for anti-JCV antibody index
testing
The recommended algorithm for the management of
immunosuppressant-naïve patients with MS based on anti-JCV
antibody status and index value is shown in ﬁgure 1. Note that
this algorithm should be used in conjunction with the risk strati-
ﬁcation table (see online supplementary data, table S1A).
It is recommended that all new patients being assessed for
natalizumab are tested for anti-JCV antibody index status before
(or around the time of, in highly active disease) initiating treat-
ment to aid treatment duration decisions. Index testing should
be performed in the event of positive anti-JCV antibody status.
Given that the initial year of therapy is associated with a low
risk of developing PML (1 in 10 000 to 1 in 1000),16 patients—
irrespective of their baseline anti-JCV antibody status—may not
then require further anti-JCV antibody monitoring for up to
12 months after initiating natalizumab.
For existing natalizumab patients, or those who have been on
treatment for 12 months or longer, the consensus panel recom-
mends that monitoring should be adapted based on anti-JCV
antibody status with the aim of guiding subsequent patient man-
agement. In the absence of real-world data, it is suggested that
extending the use of index into the current six-monthly
anti-JCV antibody testing schedule is a pragmatic approach for
anti-JCV antibody-negative patients or antibody-positive patients
found to have anti-JCV antibody index levels ≤1.5. For those
with an anti-JCV antibody index >1.5, further index testing is
not mandatory.
The stability of the anti-JCV antibody test over time and the
prognostic signiﬁcance of changes in the index are not known.
Therefore, the frequency of the testing may need adaptation as
evidence emerges. The consensus group suggests reviewing this
recommendation as more data emerges. As there are insufﬁcient
data at the time of writing to predict PML risk based on chan-
ging antibody level, the consensus group recommends that the
cut-offs described here are used and ongoing risk calculation
should be based on the highest level obtained. As shown in
ﬁgure 1, if at any time anti-JCV antibody-negative patients sero-
convert to positive status, the consensus panel recommends
reverting to the testing schedule recommended in this algorithm
for their index level. Likewise, if anti-JCV antibody-positive
patients with an index value ≤1.5 switch to an index value
>1.5 during natalizumab therapy, that is, if they move from a
lower to a higher PML risk, they should be managed as per the
algorithm (ie, further index testing is not mandatory). The con-
sensus group recommends that patients with an index value
>1.5 should be managed as per this high-positive value irre-
spective of whether they subsequently convert to a lower index
value, in the absence of clinical data supporting index testing
beyond this marker.38 There are currently insufﬁcient data to
determine the prevalence and clinical signiﬁcance of patients
who may move from high-index to low-index levels.38
Given the clinical impact of natalizumab, a positive test for
anti-JCV antibodies is not a contraindication for natalizumab
treatment; neither is an anti-JCV antibody index >1.5 a contra-
indication to continue natalizumab treatment. Indeed, many
patients who do not develop PML are likely to have high levels,
although such patients should have intensive MRI monitoring
(as described in the next section). The risks and beneﬁts of treat-
ment should be re-evaluated at appropriate intervals, which will
be determined by the patient’s disease course and wishes.
The consensus algorithm outlined here emphasises the deter-
mination of a patient’s JCV status—either anti-JCV antibody-
positive or negative. The STRATIFY JCV DxSelect ELISA has
been reported to have a false-negative rate of 2.2%.37 However,
some studies suggest that the false-negative rate may be
higher.39 40
The false-negative rate reinforces the necessity for continued
clinical vigilance alongside scheduled paraclinical monitoring.
Furthermore, sensitive methods for the detection of JCV DNA,
such as PCR-based analysis of CSF, may be utilised alongside
serological testing, particularly for natalizumab-treated patients
with an increased risk of PML development.
Recommendations for the frequency and type of MRI
screening in patients with varying index-associated PML
risks
Data are emerging that suggest MRI evidence of PML may be
evident up to 6 months before the onset of symptoms.7 12 The
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majority of current data, however, support the brain MRI-based
detection of PML at 3–4 months prior to symptoms.8 10 17 36 41 42
Such lesions generally occur in brain areas not previously
affected by MS and, depending on the location of lesions,
patients may remain asymptomatic for several months.7 33 36
Emerging data have characterised the lesion pattern in early
Figure 1 Algorithm for MRI-based PML safety monitoring during natalizumab therapy, utilising anti-JCV antibody status and anti-JCV antibody
index level. DWI, diffusion-weighted imaging; FLAIR, ﬂuid-attenuated inversion recovery; MS, multiple sclerosis; PML, progressive multifocal
leukoencephalopathy.
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scans from symptomatic patients with PML (see below),43 44
although the characteristics of asymptomatic lesions are poorly
characterised because of the small numbers of patients. A study
of 18 patients with natalizumab-associated PML lesions reported
frontal and parietal lobe involvement in 77.8% and 22.2% of
patients, respectively. Most patients presented with focal lesions
(72.2%), usually in one lobe (66.7%), with cortical grey matter
(83.3%) and cortical grey and white matter involvement
(72.2%). Forty per cent did not show high-signal-intensity
lesions.45
It is not yet known whether all patients developing PML pass
through a presymptomatic phase with MRI abnormalities. de
Toffol et al46 reported the case of a patient with AIDS-related
PML who had a normal MRI. In addition, PML associated with
natalizumab has occurred with JC granule cell neuronopathy of
the cerebellum,47 although based on present evidence this pres-
entation appears to be rare. In the latter case, the MRI would
not necessarily show any classic PML lesions.48 49
Fluid-attenuated inversion recovery (FLAIR) has been shown
to be more sensitive than T2-weighted MRI for the detection of
PML-associated lesions. Diffusion-weighted imaging (DWI) may
be useful for detection of PML within conﬂuent MS lesions.1
Gadolinium-enhancement has been reported in up to 43% of
MRI scans at diagnosis of natalizumab-associated PML, typically
evident in the vicinity of T2-hyperintense lesions, and may be
present in the early phases (ie, when T2 hyperintensity is
already present) or later in the disease course.1 14 33 50 In
general, contrast enhancement is variable and is not diagnostic
of PML.1 14
A recent report has additionally suggested that frontal, par-
ietal and thalamic punctuate gadolinium-enhancing lesions may
be apparent prior to T2 hyperintensity. These lesions were tran-
sient, disappearing after 6 weeks, and preceded the onset of
PML symptoms and new T2 hyperintense lesions by around 2
months.50 Gadolinium-enhancement is not recommended for
routine MRI safety monitoring of patients receiving natalizu-
mab; although it is useful for disease activity scans.
Evidence from 40 natalizumab-treated patients with MS diag-
nosed with PML suggests that a PML lesion may be deﬁned by
the following MRI criteria: subcortical location; a T2/FLAIR
hyperintense, T1 hypointense, and DW hyperintense signal; a
border well-deﬁned within the cortical grey matter and ill-
deﬁned in the white matter; with punctuate T2-hyperintense
lesions in the immediate vicinity of the main lesion.43 Better
outcomes have been reported when early PML lesions are loca-
lised to a single lobe of the brain and affect the frontal
lobes.7 17
The ﬁndings described above suggest that it may be possible
to identify presymptomatic PML by performing more frequent
MRI scans, especially in higher PML risk patients. It is import-
ant to bear in mind that no new activity on an MRI does not
exclude PML. If clinical suspicion of PML remains, the consen-
sus panel recommends that the physician should continue to
serially assess the patient clinically and perform CSF analysis
and MRI until satisfactory evidence is obtained. Hence, ongoing
clinical vigilance remains paramount and should not be rele-
gated or replaced by the testing and monitoring regimens sug-
gested in the algorithm.
The consensus reached regarding the frequency of MRI scan-
ning within the PML monitoring algorithm is based on the
expert opinion of authors, in the absence of peer-reviewed evi-
dence of the positive and negative predictive values of MRI scan-
ning at various time points prior to PML diagnosis (ﬁgure 1). It is
recommended that all new patients are scanned prior to initiating
natalizumab and at least annually on treatment. This provides a
recent reference MRI, which may be used to distinguish new
lesions in patients that develop new or worsening neurological
symptoms or signs once on therapy. Any new lesions on subse-
quent scans that were not evident on the previous most recent
scan should trigger clinical consideration as to whether further
investigation is necessary (ie, CSF analysis).1
For those already being treated with natalizumab, or after
12 months of treatment, the frequency of MRI monitoring
should be adapted based on JCV status and—for anti-JCV
antibody-positive patients—their index levels. MRI should, the
consensus panel recommends, be performed in the event of
unexpected clinical worsening or a suspicious clinical course.
Anti-JCV antibody-positive patients who choose to remain on
natalizumab therapy should have annual MRI scans, until they
have been on treatment for 18 months. After this time, the fre-
quency of MRI is recommended to be increased to a minimum
6-monthly for index ≤1.5 and 3–4 monthly for index >1.5.
Based on the available data among natalizumab-related PML
cases, the risk of PML increases after 24 months of natalizumab
therapy. However, in the opinion of the consensus group, in
order to detect early asymptomatic evolving PML lesions on
MRI, the frequency of scanning should increase after 18 months
of natalizumab therapy.
A limited cerebral MRI is recommended for safety monitoring
for those requiring at least 6-monthly, or 3 to 4-monthly MRI
scans using a minimum of an axial FLAIR and DWI, which could
be extended if a suspicious ﬁnding is discovered.38 43 These scans
could be performed alongside annual MRI scans to assess efﬁ-
cacy, with or without gadolinium, based on local protocols.
Imaging should be performed and reviewed in all cases by a neu-
roradiologist or a radiologist trained in identifying PML.
Diagnosis and initial management of suspected PML
The differential diagnosis of new lesions is key in the early iden-
tiﬁcation of PML. Any new lesions beyond 18 months of
therapy, or in the appropriate clinical context, should be treated
with suspicion. Any MRI-associated changes suspected of being
caused by PML that occur in immunocompromised patients
should be classiﬁed as being ‘radiologically-suspected PML’.36 If
PML is suspected, further dosing of natalizumab should be
delayed and the patient and lesion(s) carefully monitored until
PML has been, as far as clinically possible, excluded.13 A nega-
tive CSF does not exclude PML, and each clinician needs to
determine the optimal management based on each patient’s clin-
ical characteristics. However, because of a lack of evidence the
consensus group was unable to make deﬁnitive recommenda-
tions on the exact timings or number of repeat CSF tests where
clinical suspicion of PML persists, or regarding alternative
methods such as CSF index testing and local practices should be
followed until further information emerges on this issue.51
The differential diagnosis of MS progression and PML may
be further assisted based on speciﬁc MRI-associated features
(table 1).1 17 43 Clinicians should evaluate the patient to deter-
mine whether symptoms indicative of neurological dysfunction
are present and, if so, whether these symptoms are typical of
MS and, therefore, indicative of treatment failure, or possibly
suggestive of PML.13
Current criteria for deﬁnitive diagnosis of PML, from which
the PML risk ﬁgures referred to in this paper are derived, are:
(A) based on clinical presentation, the presence of JCV DNA in
the CSF, and MRI ﬁndings suggestive of PML; or (B) via the
detection of PML on histopathology of biopsy material in com-
bination with the presence of JCV by electron microscopy and/
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or immunohistochemistry, or JCV and/or JCV DNA via (quanti-
tative) PCR (qPCR).17 6
There is emerging opinion that a tiered approach to PML
case classiﬁcation based on the degree of diagnostic certainty
may be more appropriate than the current diagnostic criteria.
This includes the proposal that in asymptomatic patients, a
‘probable PML’ diagnosis can be made (which should be
managed as PML), based on pathological MRI ﬁndings consist-
ent with PML, and, JCV-positive CSF.6 12 52 53 However, it is
important to emphasise that if radiological results are suggestive
of PML, a negative CSF JCV result cannot rule out the potential
for later diagnosis.6 52 53 In the early stages of the natural
history of PML, JCV may not be evident in the cerebrospinal
ﬂuid (CSF) because viral loads are below the sensitivity of the
virus assay. In one study of 28 patients with
natalizumab-associated PML, 16 initially had undetectable JCV
DNA as the CSF viral load was below the threshold of
500 copies/mL.33
Furthermore, even small lesions associated with JCV-negative
CSF can be symptomatic.54 Thus, if a negative result is obtained
but clinical suspicion of PML remains high based on MRI ﬁnd-
ings and/or symptomatic presentation, the consensus panel
recommends that CSF testing should be repeated over several
months if necessary, or brain biopsy performed.36 A reference
laboratory that can detect a low CSF copy number (ie,
50 copies/mL) should be utilised.33
Early detection of PML, followed by rapid cessation of natali-
zumab therapy and plasma exchange to restore immune function,
appears to be associated with a good prognosis,7–11 36 although
deﬁnitive evidence is needed. Immune reconstitution inﬂamma-
tory syndrome (IRIS) occurs in almost all natalizumab-associated
patients with PML within days or several weeks after withdrawal
or removal of natalizumab by plasma exchange.13 55 While there
is no conclusive evidence that an early immune reconstitution
produces better outcomes compared to natalizumab washout,
plasmapheresis with immunoadsorption could be considered,
which would theoretically remove drug more rapidly. It is note-
worthy that in an attempt to mitigate the risk of IRIS, some
centres are not currently using plasma exchange in favour of
allowing natural wash-out of natalizumab.
Table 1 Clinical and MRI features that may be considered in the differential diagnosis of MS and PML
Feature Multiple sclerosis Progressive multifocal leukoencephalopathy
Clinical features
Onset Acute Subacute
Evolution ▸ Over hours to days
▸ Normally stabilises
▸ Resolves spontaneously even without therapy
▸ Over weeks
▸ Progressive
Clinical presentation ▸ Diplopia
▸ Paresthesia
▸ Paraparesis
▸ Optic neuritis
▸ Myelopathy
▸ Aphasia
▸ Behavioural and neuropsychological alteration
▸ Retrochiasmal visual deficits
▸ Hemiparesis
▸ Seizures
MRI features
Aspect and location of
new lesions
Focal, generally periventricular in location. Lesions occur in all
areas of the brain particularly the corpus callosum and spinal
cord
Diffuse. Generally large >3 cm lesions in a unifocal, multifocal or
widespread distribution. Subcortical location rather than periventricular.
Affecting U fibres and extending into the gyrus. Cortical GM involvement in
50% of cases. Posterior fossa less frequent site. Spinal cord presentation
rare
Borders Sharp edges; mostly round or flame shaped (especially
periventricular lesions), confluent with other lesions; U-fibres
may be involved
Irregular in shape. Ill-defined border toward the white matter, sharp border
toward the cortical grey matter
Mode of extension Initially focal, lesions enlarge within days or weeks and later
decrease in size within months
Lesion volume increases continuously, and sometimes rapidly to contiguous
(multifocal) and non-contiguous regions (widespread) confined to white
matter tracts, sparing the cortex
Mass effect Large acute lesions may have mass effect No mass effect even in large lesions apart from when inflammatory
response is present
On T2-weighted
sequence
Homogeneous hyperintensity Diffuse hyperintensity, little irregular signal intensity within the lesions, can
have a punctate microcystic appearance. Small punctate T2 lesions may be
seen in proximity to the lesion
On T1-weighted
sequence
Acute lesions: hypointense (due to oedema) or isointense.
Increasing signal intensity over time in 80%; decreasing signal
intensity (axonal loss) in about 20%
Slightly hypointense at onset, with signal intensity decreasing over time in
the affected area; no reversion to isointense signal intensity
On FLAIR sequence Hyperintense, sharply delineated FLAIR is the preferred sequence for PML diagnosis, because of the
subcortical location
Contrast enhancement Acute lesions: homogeneous nodular or ring enhancement, with
sharp edges eventual resolution over 1–2 months. Chronic
lesions: no enhancement
Less than half of the cases to date have shown some enhancement at the
time of presentation often with a patchy or punctate appearance. Rim
enhancement at leading edge can be seen in larger lesions
Diffusion-weighted
imaging
Acute lesions hyperintense. Chronic lesions isointense. Conforms
to shape of lesions on FLAIR and T2W
Acute PML lesions are hyperintense but not specific for PML. Helpful to
detect new PML lesions within confluent areas of chronic WM disease. ADC
maps not helpful
Atrophy Focal atrophy possible, due to focal white-matter degeneration;
no progression
No focal atrophy initially, but can be seen in late stages of PML progression
It should be noted that none of the MRI features are pathognomonic of MS or PML. Adapted from Physician information and management guidelines for multiple sclerosis patients on
Tysabri therapy, Biogen, V.14, 22 May 2015 (permission obtained).
ADC, Apparent diffusion coefficient; FLAIR, fluid-attenuated inversion recovery; GM, grey matter; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy; T2W, T2
weighted; WM, white matter.
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Once the clinician has excluded PML (if necessary, by repeat-
ing clinical, imaging and/or laboratory investigations if clinical
suspicion remains), dosing of natalizumab may resume.13
CONCLUSIONS
The overall aim of this consensus paper was to present a simple
and pragmatic algorithm to support the introduction of
anti-JCV antibody index testing into standard PML safety proto-
cols, in order to allow those JCV positive patients who wish to
continue treatment to be managed with a more individualised
analysis of their risk. Fundamental to these revised protocols is
enhanced MRI monitoring, which should be guided by anti-JCV
antibody index levels. This consensus has been generated by
clinicians to facilitate the evolution of the management of
patients with MS. While not a scientiﬁc paper, the authors have
conducted rigorous analysis of the limited data available, and
have had considerable discussion regarding the application of
index in the context of current practice. No data were available
at the time of writing to support some of the guidance and, in
such cases, recommendations were based instead on the clinical
experience of the authors. There is a need for more data around
the positive and negative predictive value of MRI in the detec-
tion of presymptomatic PML, to better inform safety protocols.
At the time such data were available, this guideline may need to
be updated. Additionally, this recommendation is intended to
outline best practice and does not take into account local varia-
tions in MRI resource provision.
The introduction of the anti-JCV antibody index into stand-
ard clinical practice should provide patients with MS and clini-
cians with more tangible evidence on which to base the decision
whether or not to continue natalizumab treatment. For instance,
further studies should assess the stability of the index value over
time using serial data and ascertain the speciﬁcity and selectivity
of other emerging and potential biomarkers.
The greater understanding of individual patient risk provided
by the new test may help balance the concern of PML with the
beneﬁts that natalizumab offers to patients: particularly those
who are anti-JCV antibody-positive with a low index value
(≤1.5) in whom, before the application of stratiﬁcation by
index, the decision whether or not to continue natalizumab
treatment would be difﬁcult. At the same time, the improved
understanding of PML risk among anti-JCV antibody-positive
patients with a high index value (>1.5) may assist decisions to
discontinue therapy, based on the views of unacceptable levels
of risk. The stability of the anti-JCV antibody test over time and
the prognostic signiﬁcance of a rising index are not known.
Therefore, the consensus group suggests reviewing this recom-
mendation as new data emerges.
PML is a severe and well-documented complication of natali-
zumab treatment. There is evidence to show PML treatment
outcomes are better if it can be detected in a presymptomatic
state, through clinical vigilance, and appropriate MRI monitor-
ing protocols applied according to JCV risk and stratiﬁed using
the index test result.
The aim of these guidelines is to support clinicians in counsel-
ling patients on the risk beneﬁt proﬁle of starting natalizumab
and once on treatment, early detection of PML before it can
cause signiﬁcant disability or death, although further data are
needed to fully characterise the impact of early identiﬁcation on
clinical outcomes. Such early or presymptomatic diagnosis
requires improved identiﬁcation of at-risk patients, sustained
clinical vigilance, and evidence-led MRI monitoring protocols,
such as those proposed by the algorithm presented here.
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